ReShape Lifesciences Delays 10-Q Filing

ReShape Lifesciences ( (RSLS) ) has released a notification of late filing.

ReShape Lifesciences Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The delay is primarily due to the additional time required to compile information for its financial statements and related disclosures, particularly to account for a reverse stock split executed on May 9, 2025. The company anticipates submitting the report within the additional time allowed by Rule 12b-25, which provides a five-day extension. Importantly, ReShape Lifesciences does not expect any significant changes in its financial results compared to the same period last year. The notification was signed by Thomas Stankovich, the Chief Financial Officer, emphasizing the company’s commitment to compliance.

Spark’s Take on RSLS Stock

According to Spark, TipRanks’ AI Analyst, RSLS is a Underperform.

ReShape Lifesciences is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The technical indicators show a bearish trend with potential oversold conditions. Valuation is poor due to a negative P/E ratio. Despite some positive developments highlighted in the earnings call, such as revenue growth and cost reductions, the overall outlook remains concerning due to financial instability and competitive pressures. The recent board resignation further complicates the situation by potentially affecting compliance and investor confidence.

To see Spark’s full report on RSLS stock, click here.

More about ReShape Lifesciences

Average Trading Volume: 743,544

Technical Sentiment Signal: Sell

Current Market Cap: $2.82M

See more insights into RSLS stock on TipRanks’ Stock Analysis page.